CIRRICULUM VITAE Costas A. Lyssiotis, Ph.D. Assistant Professor, Department of Molecular and Integrative Physiology Internal Medicine, Division of Gastroenterology University of Michigan The Cancer Center 1150 E. Medical Center Drive Lyssiotis Laboratory: Room 6130 Ann Arbor, MI 48109, USA
+1 (734) 615-9133
[email protected] www.costaslyssiotis.com
I. EDUCATION: The Scripps Research Institute, La Jolla, CA Ph.D. Chemical Biology | Insight into the Reprogramming of Cell Fate with Small Molecules National Science Foundation Fellow
04/2010
University of Michigan, Ann Arbor, MI B.S. Chemistry and Biochemistry Graduated with distinction and highest honors in chemistry
12/2004
II. RESEARCH EXPERIENCE: Weill Cornell Medical College, New York, NY Pancreatic Cancer Action Network / AACR Pathway to Leadership Postdoctoral Fellow The Cancer Center, Department of Medicine Mentor: Prof. Lewis C. Cantley
06/2013 – 06/2015
Harvard Medical School, Boston, MA Damon Runyon Cancer Research Foundation Postdoctoral Fellow Department of Systems Biology Beth Israel Deaconess Medical Center, Division of Signal Transduction Mentor: Prof. Lewis C. Cantley
10/2010 – 05/2013
École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland Human Frontiers Science Program Short-term Postdoctoral Fellow Swiss Institute for Experimental Cancer Research Mentor: Prof. Douglas Hanahan
06/2010 – 09/2010
The Scripps Research Institute, La Jolla, CA National Science Foundation Predoctoral Fellow Skaggs Institute for Chemical Biology, Department of Chemistry Mentor: Prof. Peter G. Schultz
07/2005 – 04/2010
University of Michigan, Ann Arbor, MI Undergraduate Honors Thesis Research Department of Chemistry and Chemical Biology Mentor: Prof. Gary D. Glick
01/2002 – 05/2005
III. HONORS AND AWARDS: Tri-Institutional Breakout Prize for Junior Investigators National Institutes of Health Clinical Loan Repayment Program Award Outstanding Presentation Award, AACR Special Conference on Pancreatic Cancer
05/2015 10/2014 – 09/2016 05/2014
Dale F. Frey Award for Breakthrough Scientists Damon Runyon Cancer Research Foundation
10/2014 – 09/2016
Pathway to Leadership Award Pancreatic Cancer Action Network / American Association for Cancer Research
07/2013 – 06/2018
National Cancer Institute Scholarship, Keystone Symposium
02/2013
Scholar-in-Training Award, American Association for Cancer Research-Aflac
06/2012
Damon Runyon Postdoctoral Fellowship
10/2010 – 06/2013 Page 1 of 6
Human Frontiers Science Foundation Short Term Postdoctoral Fellowship Susan G. Komen Postdoctoral Fellowship (declined) National Science Foundation Predoctoral Fellowship
06/2010 – 09/2010 2010 05/2006 – 04/2009
IV. PUBLICATIONS: 25. Chakrabarti G, Moore Z, Luo X, Ilcheva M, Ali A, Anderson GG, Padanad M, Scaglioni PP, Cantley LC, Kimmelman AC, DeBerardinis RJ, *Lyssiotis CA [co-senior authors], *Boothman DA. Targeting Glutamine Metabolism Sensitizes Pancreatic Cancer to PARP1-driven Metabolic Catastrophe Induced by ß-lapachone. Cancer & Metabolism, In Press. 24. Hu H, Juvekar A, Lyssiotis CA, Lien EC, Albeck JG, Varma G, Hung YP, Wang X, Ullas S, Tolan DR, Grant AK, Asara JM, Cantley LC, Wulf GM. Phosphoinositide 3-Kinase Regulates Glycolysis Through an AKT-independent Mechanism that Mobilizes Aldolase A Release from the Actin Cytoskeleton. Cell, In Revision. 23. Sadanandam A, Wullschleger S, Lyssiotis CA, Grötzinger C, Barbi S, Bersani S, Körner J, Wafy I, Mafficini A, Lawlor RT, Asara JM, Blaker H, Cantley LC, Wiedenmann B, Scarpa A, Hanahan D. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Metastatic, Developmental, and Metabolic Characteristics. Cancer Discovery, In Press. 22. Glick GD, Rossignol R, Lyssiotis CA, Wahl D, Lesch C, Sanchez B, Liu X, Hao LY, Taylor C, Hurd A, Ferrara JL, Tkachev V, Byersdorfer C, Boros L, Opipari AW. Targeting Increased Anaplerotic Metabolism of Pathogenic T cells to Treat Immune Disease. J Pharmacol Exp Ther 2014;351:298–307. 21. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, KostAlimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Carugo A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming J, Cantley LC, DePinho R, Draetta G. Oncogene Ablation-Resistant Pancreatic Cancer Cells Depend on Mitochondrial Function. Nature 2014;30:628– 32. » Highlighted in Nature Reviews Clinical Oncology 2014;11:562. » Highlighted in Cancer Discovery 2014;4:OF14. 20. Yeo H, Lyssiotis CA, Zhang Y, Ying H, Asara JM, Cantley LC, Paik JH. FoxO3 Coordinates Metabolic Pathways to Maintain Redox Balance in Neural Stem Cells. EMBO J 2013;32:2589–2602. 19. Deshmukh VA, Tardif V, Lyssiotis CA, Green CC, Kerman B, Kim HJ, Padmanabhan K, Swoboda JG, Ahmad I, Kondo T, Gage FH, Theofilopoulos AN, Lawson BR, Schultz PG, Lairson LL. A Regenerative Approach to the Treatment of Multiple Sclerosis. Nature 2013;502:327–332. » Selected as the best science paper in MS. Multiple Sclerosis 2014;20:1814–1816. » Highlighted in Nature Reviews Drug Discovery 2013;12:905. » Highlighted in Nature Reviews Neurology 2013;9:660. » Highlighted in Nature Chemical Biology 2013;9:754. » Highlighted in Nature 2013;502:314–315. 18. Bettaieb A, Bakke J, Nagata N, Matsuo K, Xi Y, Liu S, AbouBechara D, Melhem R, Stanhope K, Cummings B, Graham J, Bremer A, Zhang S, Lyssiotis CA, Zhang Z-Y, Cantley LC, Havel PJ, Haj FG. Protein-Tyrosine Phosphatase 1B Regulates Pyruvate Kinase M2 Tyrosine Phosphorylation. J Biol Chem 2013;288:17360–17371. 17. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, Ostos LC, Lannon WA, Grotzinger C,, Olshen AB, Wiedenmann B, Cantley LC, Gray JW, Hanahan D. A Colorectal Tumor Classification System that Associates Cellular Phenotype and Responses to Therapy. Nature Medicine 2013;19:619–625. » Highlighted in Nature Reviews Clinical Oncology 2013;10:303. » Highlighted in Nature Reviews Cancer 2013;13:380–381. 16. *Son J, *Lyssiotis CA [*co-lead authors], Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Fleming JB, Bardeesy N, Asara JM, Haigis MC, DePinho RA, Cantley LC, Kimmelman AC. Glutamine Supports Pancreatic Cancer Growth Through a KRAS-Regulated Metabolic Pathway. Nature 2013;496:101–105. » Highlighted in Nature Biotechnology 2013;31:505–507. » Highlighted in Nature Reviews Gastroenterology and Hepatology 2013;10:260. » Highlighted in Nature Reviews Cancer 2013;13:293. » Highlighted in Cancer Discovery 2013;3:483. 15. Yang W, Zheng Y, Xia Y, Lyssiotis CA, Aldape K, Cantley LC, Lu Z. ERK1/2-Dependent Phosphorylation and Nuclear Translocation of PKM2 Promotes the Warburg Effect. Nature Cell Biology 2012;14:1295–1304. » Highlighted in Science Daily 2012. » Highlighted in Nature Reviews Cancer 2012;19:5. LYSSIOTIS, Costas
Page 2 of 6
14. Shyh-Chang N, Locasale JW, Lyssiotis CA, Zheng Y, Teo RY, Ratanasirintrawoot S, Zhang J, Onder T, Unternaehrer JJ, Zhu H, Asara JM, Daley GQ, Cantley LC. Influence of Threonine Metabolism on S-AdenosylMethionine and Histone Methylation. Science 2012;339:222–226. » Highlighted in Science 2012;339:148–150. 13. Juvekar A, Burga L, Hu H, Lunsford E, Ibrahim YH, Balmana J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM. Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for a Mouse Model of BRCA1-Related Breast Cancer. Cancer Discovery 2012;2:1049–1063. 12. *Ying H, *Kimmelman AC, *Lyssiotis CA [*co-lead authors], Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik J, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA. Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. Cell 2012;149:656–670. » Highlighted in Nature Reviews Clinical Oncology 2012;9:368. » Highlighted in Cancer Research 2012;72:11. » Highlighted in Science Business eXchange 2012. » Exceptional article [12], as evaluated by Faculty of 1000. 11. Gao D, Inuzuka H, Tan MM, Fukushima H, Locasale JW, Liu P, Wan L, Zhai B, Chin YR, Shaik S, Lyssiotis CA, Gygi SP, Toker A, Cantley LC, Asara JM, Harper JW, Wei W. mTOR Drives its Own Activation via SCFβ-TRCPdependent Degradation of the mTOR Inhibitor DEPTOR. Molecular Cell 2011;44:290–303. » Highlighted in Nature Reviews Molecular Cell Biology 2011;12. 10. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattiani K, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki A, Anastasiou D, Mullarky E, Sasaki M, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM , Brugge JS, Cantley LC, Vander Heiden MG. Phosphoglycerate Dehydrogenase Diverts Glycolytic Flux and Contributes to Oncogenesis. Nature Genetics 2011;43:869–874. » Highlighted in Nature Reviews Cancer 2011;11:621. » Highlighted in Nature Biotechnology 2011;29:809. » Highlighted in Cell Metabolism 2011;14:285–286. » Highlighted in Science Business eXchange 2011;4:30. » Highlighted in Pigment Cell Melanoma Research 2011. 9.
Sadanandam A, Futakuchi M, Lyssiotis CA, Gibb WJ, Singh RK. A Mouse Model that Mimics the Osteolytic Microenvironment of Human Breast Cancer Bone Metastasis is Used to Predict a Therapeutic Agent that Targets the Tumor-Bone Interface. BMC Cancer 2011;11:304–317.
8.
*Staerk J, *Lyssiotis CA [*co-lead authors], Foreman RK, Bollong M, Zhu S, Garcia M, Bouchez L, Lairson LL, Charette BD, Brinker A, Cho CY, Jaenisch R, Schultz PG. Inhibition of c-Src kinase activity functionally substitutes for Sox2 during the direct reprogramming of murine fibroblasts to iPS cells. Angew Chem Int Ed 2011;50:5734–5736.
7.
Zhu S, Wurdak H, Wang Y, Galkin A, Tao H, Li J, Lyssiotis CA, Yan F, Tuu B, Miraglia L, Walker J, Sun F, Orth A, Harris J, Schultz PG, Wu X. A Genomic Screen Identifies TYRO3 as a MITF Regulator and Melanoma Oncogene. Proc Nat Acad Sci 2009;106:17025–17030.
6.
Blatt NB, Boitano AE, Lyssiotis CA, Opipari AW, Glick GD. Bz-423 Superoxide Signals B Cell Apoptosis via Mcl-1, Bak, and Bax. Biochem Pharm 2009;78:966–973.
5.
*Lyssiotis CA [*co-lead authors], *Foreman RK, *Staerk J, Garcia M, Mathur D, Markoulaki S, Hanna J, Lairson LL, Charette BD, Bouchez L, Kunick C, Brinker A, Cho CY, Schultz PG, Jaenisch R. Reprogramming of Murine Fibroblasts to iPS Cells With Chemical Complementation of Klf4. Proc Nat Acad Sci 2009;106:8912–8917. » Highlighted in Nature Cell Biology 2009;11: 796. » Highlighted in Nature Reports Stem Cells, May 2009. » Highlighted in Regenerative Medicine 2009;4:371–374. » Highlighted in Assay and Drug Development Technologies 2009.
4.
Zhu S, Wurdak H, Wang J, Lyssiotis CA, Peters EC, Cho CY, Wu X, Schultz PG. A Small Molecule Primes Embryonic Stem Cells for Differentiation by Targeting NME2. Cell Stem Cell 2009;4:416–426. » Highlighted in Cell Stem Cell 2009;4:373–374. » Highlighted in Nature Chemical Biology 2009;5:456–457. » Highlighted in Molecular Interventions 2009;9, 167.
3.
Blatt NB, Boitano AE, Lyssiotis CA, Opipari AW, Glick GD. Bz-423 Superoxide Signals Apoptosis via Selective Activation of JNK, Bak, and Bax. Free Rad Biol Med 2008;45:1232–1242.
LYSSIOTIS, Costas
Page 3 of 6
2.
Lyssiotis CA, Walker J, Wu C, Kondo T, Schultz PG, Wu X. Inhibition of Histone Deacetylase Activity Induces Developmental Plasticity in Oligodendrocyte Precursor Cells. Proc. Nat. Acad. Sci. 2007;104:14982–14987. » Highlighted in Cell 2007;131:197–198.
1.
Bednarski JJ, Lyssiotis CA, Roush RR, Boitano AE, Glick GD, Opipari AW. A Novel Benzodiazepine Increases the Sensitivity of B Cells to Receptor Stimulation with Synergistic Effects on Calcium Signaling and Apoptosis. J Biol Chem 2004;279:29615–29621.
V. REVIEWS: 5.
Getting to Know Cancer Taskforce*. (2015) A Broad-Spectrum Integrative Design for Cancer Prevention and Therapy. Seminars in Cancer Biology. In Press. [*member of >200 author taskforce]
4.
Hirschey MD, *DeBerardinis RJ, *Diehl AME, *Drew J, *Frezza C, *Green MF, *Jones LW, *Ko YH, *Le A, *Lea MA, *Locasale JW, *Longo VD, *Lyssiotis CA, *McDonnell E, *Mehrmohamadi M, *Michelotti G, *Muralidhar V, *Murphy MP, *Pedersen P, *Poore B, *Raffaghello L, *Rathmell JC, *Sivanand S, *Vander Heiden MG, *Wellen KE. (2015) A Broad-Spectrum Integrative Design for Cancer Prevention and Therapy. Chapter 7, Dysregulated Metabolism Contributes to Oncogenesis. Getting to Know Cancer, Halifax Project. Seminars in Cancer Biology. In Press. [*equal contribution; authors listed alphabetically]
3.
Lairson LL, Lyssiotis CA, Zhu S, Schultz PG. Small Molecule-Based Approaches to Adult Stem Cell Therapies. Annu Rev Pharmacol Toxicol 2012;6:107–125.
2.
Lyssiotis CA, Anastasiou D, Locasale J, Vander Heiden MG, Cantley LC. Cellular Control Mechanisms that Regulate Pyruvate Kinase M2 Activity and Promote Cancer Growth. Biomed Res 2012;23:213–217.
1.
Lyssiotis CA, Lairson LL, Boitano AE, Wurdak H, Zhu S, Schultz PG. Chemical Control of Stem Cell Fate and Developmental Potential. Angew Chem Int Ed 2011;50:200–242.
VI. COMMENTARIES: 6.
Lyssiotis CA, Cantley LC. Acetate Fuels the Cancer Engine. Cell 2014;159:1492–1494.
5.
Lyssiotis CA, Cantley LC. Metabolic Scavenging in Pancreatic Cancer. Clin Can Res 2014;20:6–8.
4.
Lyssiotis CA, Cantley LC. Metabolic Syndrome: F Stands for Fructose and Fat. Nature 2013;502:181–182.
3.
Lyssiotis CA, Son J, Cantley LC, Kimmelman AC. Pancreatic Cancers Rely on a Novel Glutamine Metabolism Pathway to Maintain Redox Balance. Cell Cycle 2013;12:1987–1988.
2.
Lyssiotis CA, Cantley LC. SIRT6 Puts Cancer Metabolism in the Driver’s Seat. Cell 2012;151:1155–1156.
1.
Lyssiotis CA, Vander Heiden MG, Muñoz-Pinedo C, Emerling BM. Emerging Concepts: Linking Hypoxic Signaling and Cancer Metabolism. Cell Death Dis 2012;3:e303.
VII. BOOK CHAPTERS: 2.
Lien E, Lyssiotis CA, Cantley LC. Metabolic Reprogramming by the PI3K/AKT- mTOR Pathway in Cancer. Kramer T, Schmitt CA. eds. In: Recent Results in Cancer Research. Metabolism in Cancer. New York, NY. Springer Publishing Group. Invited Book Chapter. In Press.
1.
Lyssiotis CA, Charette BD, Lairson LL. Reprogramming Developmental Potential. Lakshmipathy U, et al., eds. In: Emerging Technology Platforms for Stem Cells. New York, NY. John Wiley, Sons Press, Inc. 2009;51–85.
VIII. PATENTS: 5.
Cantley LC, Lairson LL, Lyssiotis CA, Mullarky EM. Phosphoglycerate Dehydrogenase Inhibitors. Disclosure submitted, August 2015.
4.
DePinho R, Cantley LC, Kimmelman A, Ying H, Lyssiotis CA. Methods for Diagnosing and Treating Oncogenic Kras-Associated Cancer. U.S. Patent Number 2015/0126580, filed December 20, 2011 and issued May 7, 2015. International Patent Number 14/367,341, filed June 20, 2014.
3.
Kimmelman AC, Son J, Cantley LC, Lyssiotis CA. Targeting the Glutamine to Pyruvate Pathway for Treatment of Oncogenic Kras-Associated Cancer, U.S. Patent Number 2015/0110773, filed May 23, 2013 and issued April 23, 2015.
2.
Hanahan D, Gray J, Sadanandam A, Lyssiotis CA. Colorectal Cancer Classification with Differential Prognosis and Personalized Therapeutic Responses, International Patent Number WO/2014/080381 A1, filed November 26, 2013 and issued May 30, 2014.
LYSSIOTIS, Costas
Page 4 of 6
1.
Deshmukh V, Lyssiotis CA, Lairson LL, Schultz PG. Directed Differentiation of Oligodendrocytes Precursor Cells into a Myelinating Cell Fate. International Patent Number WO/2012/112933, filed February 17, 2012 and issued February 6, 2014.
XI. ONGOING RESEARCH SUPPORT: Dale F. Frey Award for Breakthrough Scientists Damon Runyon Cancer Research Foundation Exploration and Targeting of Metabolic Dependencies in Pancreatic Cancer Role: Principal Investigator; $100,000 USD
07/2015 – 06/2017
Pathway to Leadership Award Pancreatic Cancer Action Network / American Association for Cancer Research Exploration and Targeting of Metabolic Dependencies in Pancreatic Cancer Role: Principal Investigator; $600,000 USD
07/2013 – 06/2018
Lustgarten Foundation Research Grant Development of Small Molecule Inhibitors of Pancreatic Cancer Metabolism Role: Consultant (Principal Investigators: Kimmelman, Cantley, Lairson)
01/2013 – 12/2015
X. COMPLETED RESEARCH SUPPORT: Department of Defense Cancer Discovery Grant In vivo Measurement of Kras-Dependent Metabolism in Mouse Models of Pancreatic Cancer Role: co-Principal Investigator (with Kimmelman and Ying); $200,000 USD
10/2012 – 09/2014
Damon Runyon Cancer Research Foundation Fellowship Exploring the Metabolic Effects of Oncogenic Kras in Pancreatic Ductal Adenocarcinoma Role: Principal Investigator; $156,000 USD
10/2010 – 05/2013
XI. INVITED SEMINARS: Translational Oncology Program: University of Michigan Presentation Title: Defining and Exploiting Metabolic Vulnerabilities in Pancreatic Cancer
09/2015
New York Academy of Sciences: New York, NY Unique Cancer Metabolism Features Inform New Therapeutic Opportunities Conference co-Organizer
05/2015
University of Michigan: Ann Arbor, MI Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer
01/2015
Oregon Health and Science Institute: Portland, OR Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer
12/2014
National Institutes of Health, Cancer Biology, Earl Stadtman Symposium: Bethesda, MD Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer
12/2014
University of Texas, Southwestern: Dallas, TX Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer
11/2014
Sanford-Burnham Medical Research Institute: San Diego, CA Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer
10/2014
University of Southern California: Los Angeles, CA Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer
10/2014
Yale: New Haven, CT Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer
10/2014
New York Academy of Sciences, Targeting Key Vulnerabilities in Pancreatic Cancer: New York, NY Presentation Title: Exploiting Glutamine Addiction in Pancreatic Cancer
10/2014
MD Anderson Cancer Center: Houston, TX Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer
09/2014
New York University: New York, NY Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer
09/2014
MD Anderson Cancer Center, Symposium on the Future of Cancer Science: Houston, TX
06/2014
LYSSIOTIS, Costas
Page 5 of 6
Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer Lycera Corp: Ann Arbor, MI Presentation Title: Defining Metabolic Vulnerabilities in Pancreatic Cancer
05/2014
New York Academy of Sciences, Mitochondria, Metabolism and Disease: New York, NY Presentation Title: Pancreatic Cancers Depend on a Non-Canonical Glutamine Metabolism Pathway
04/2014
Beth Israel Deaconess Medical Center Affinity Research Collaborative: Boston, MA Presentation Title: Metabolic Addictions in Pancreatic Cancer
04/2013
Keystone Symposium, Tumor Metabolism: Keystone, CO Presentation Title: Glutamine Supports Pancreatic Tumor Growth and Redox Homeostasis
02/2013
Pancreatic Cancer Retreat: New Paltz, NY Presentation Title: Oncogenic Kras is Required for Pancreatic Tumor Maintenance Through the Regulation of Anabolic Glucose Metabolism
10/2012
Genomics Institute of the Novartis Research Foundation Board Meeting: San Diego, CA Presentation Title: Chemical Methods to Reprogram Developmental Potential
03/2009
Stem Cells and Regenerative Medicine World Congress: Palm Springs, CA Presentation Title: Reprogramming to iPS Cells: Chemical Complementation of Klf4
01/2009
XII. AFFILIATIONS: University of Michigan Program in Chemical Biology
2015 – present
University of Michigan Metabolomics Core
2015 – present
University of Michigan Pancreatic Cancer Research Group
2015 – present
University of Michigan Comprehensive Cancer Center
2015 – present
American Physiology Society (APS) (Member)
2015 – present
American Pancreatic Association (APA) (Member) http://american-pancreatic-association.org/
2015 – present
AACR-Grantee Network, LinkedIn Group (Moderator)
2014 – present
Deregulated Metabolism Team, Getting to Know Cancer Taskforce http://www.gettingtoknowcancer.org/
2013 – present
New York Academy of Science (Member) http://www.nyas.org/
2013 – present
American Association for Cancer Research (AACR) (Member) http://www.aacr.org/
2011 – present
Tri-Institute Cancer Metabolism Program (co-Manager)
2013 – 2015
Weill Cornell Medical College Cancer Center, Program in Cancer Metabolism
2013 – 2015
Pancreatic Cancer Action Network—New York City Affiliate Group http://www.meetup.com/pancanNYC/
2013 – 2015
Consultant, Lycera Corp. http://www.lycera.com/
2014
Research!America Advocacy Academy http://www.researchamerica.org/
2013
Consultant, American Journal Editors (reviewer) http://www.aje.com
2011 – 2013
Consultant, Rubriq (reviewer) http://www.rubriq.com
2011 – 2013
LYSSIOTIS, Costas
Page 6 of 6
